Susceptibility of Candida glabrata biofilms to echinocandins: alterations in the matrix composition
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Candidiases are the most recurrent fungal infections, especially among immunosuppressed patients. Although Candida albicans is still the most widespread isolated species, non-Candida albicans Candida species have been increasing. The goal of this work was to determine the susceptibility of C. glabrata biofilms to echinocandins and to evaluate their effect on the biofilm matrix composition, comparing the results with other Candida species. Drug susceptibilities were assessed through the determination of minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC) and minimum biofilm eradication concentration (MBEC) of caspofungin (Csf) and micafugin (Mcf). The β-1,3 glucans content of the matrices was assessed after contact with the drugs. The data suggest that, generally, after contact with echinocandins, the concentration of β-1,3 glucans increased. These adjustments in the matrix composition of C. glabrata biofilms and the chemical differences between Csf and Mcf, seem responsible and may determine the effectivity of the drug responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578 · cited 2×
“Fungal cell wall polysaccharides are significant constituents of the biofilm matrix of Candida species (Chandra et al. 2001; Kuhn et al. 2002).”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Ramage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583 · cited 1×
“Infections caused by biofilms are complicated due to inducible gene networks encoding different proteins that confer tolerance or resistance to many of the available antifungal drugs (Ramage et al. 2012).”
BackgroundResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Dispersion as an Important Step in the Candida albicans Biofilm Developmental Cycle
Uppuluri, P., Chaturvedi, A. K., Srinivasan, A., Banerjee, M., Ramasubramaniam, A. K., Köhler, J. R., Kadosh, D., & Lopez-Ribot, J. L. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000828 · Cited by 432 · cited 2×
“…and Douglas 1995; Fonseca et al. 2014; Rodrigues and Henriques 2017), C. albicans SC5314 (biofilm presenting high hyphal quantity and entanglement (Uppuluri et al. 2010; Rodrigues and Henriques 2017) and C. parapsilosis ATCC22019 (continuous biofilm carpet with clumped blastospores (Taff et al.…”
BackgroundAntifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418 · cited 3×
“In some cases, a high Csf concentration would lead to a low drug activity and, thus, to a lower biomass reduction, revealing a probable paradoxical effect (Wiederhold 2009; Perlin 2014; GilAlonso et al. 2015; Scorzoni et al. 2017).”
BackgroundEchinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · cited 2×
“Perlin DS. 2015b. Echinocandin resistance in Candida.”
BackgroundImmune Recognition of Candida albicans β‐glucan by Dectin‐1
Gow, N. A. R., Netea, M. G., Munro, C. A., Ferwerda, G., Bates, S., Mora‐Montes, H. M., Walker, L., Jansen, T., Jacobs, L., Tsoni, V., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/523110 · Cited by 314 · cited 1×
“Candida isolates display paradoxical effect more frequently when grown as biofilms compared to the planktonic form (Gow et al. 2007; Gil-Alonso et al. 2015, 2016; Scorzoni et al. 2017).”
BackgroundMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Fungal Biofilms and Drug Resistance
Jabra-Rizk, M. A., Falkler, W. A., & Meiller, T. F. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1001.030119 · Cited by 292
McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Candida glabrata: A review of its features and resistance
Rodrigues, C. F., Silva, S., & Henriques, M. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2009-3 · Cited by 268 · cited 1×
“Biofilms are communities of microorganisms embedded in an extracellular matrix (Costerton et al. 1995; Donlan and Costerton 2002), which confers significant resistance to antifungal therapy and intense host immune responses (Fonseca et al. 2014; Rodrigues et al. 2014).”
BackgroundSelf-citationPenetration of Candida Biofilms by Antifungal Agents
Al-Fattani, M. A., & Douglas, L. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3291-3297.2004 · Cited by 235
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Stevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193
Changing epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163 · cited 1×
“…spectrum (Barchiesi et al. 2005; Pappas et al. 2015; McCarty and Pappas 2016), but both echinocandins still show very good in vitro activity against clinically relevant isolates of Candida species (Pappas et al. 2007; Spreghini et al. 2012; Kohno et al. 2013; Perlin 2015a; Chapman et al. 2017).”
BackgroundDrug-Resistant Candida glabrata Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152
Changing epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx047 · Cited by 149
Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-10 · Cited by 144 · cited 1×
“Not surprisingly, the MBEC results evidenced the higher resistant profile of biofilm cells to antifungal agents than planktonic cells (Lewis et al. 2002; Al-Fattani and Douglas 2004; Ferrari et al. 2011; Grandesso et al. 2012; De Luca et al. 2012).”
ResultThe echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129 · cited 6×
“Extraction method: biofilms were formed in 24-well polystyrene microtitre plates (Orange Scientific) (Rodrigues, Gonçalves et al. 2017).”
BackgroundInfluentialSelf-citationArendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · cited 3×
“parapsilosis showed higher MIC values than the other Candida species (Arendrup et al. 2012; Arendrup and Pfaller 2012; Arendrup and Perlin 2014; Pham et al. 2014; Gil-Alonso et al. 2015).”
BackgroundResultA 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade
Tortorano, A. M., Prigitano, A., Lazzarini, C., Passera, M., Deiana, M. L., Cavinato, S., De Luca, C., Grancini, A., Lo Cascio, G., Ossi, C., et al. (2013) · Infection · doi:10.1007/s15010-013-0455-6 · Cited by 110
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99 · cited 1×
“Perlin DS. 2014.”
Cateau, E., Rodier, M.-H., & Imbert, C. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn160 · Cited by 98
Dominguez, E., Zarnowski, R., Sanchez, H., Covelli, A. S., Westler, W. M., Azadi, P., Nett, J., Mitchell, A. P., & Andes, D. R. (2018) · mBio · doi:10.1128/mbio.00451-18 · Cited by 77
Arendrup, M. C., Pfaller, M. A., & the Danish Fungaemia Study Group (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00355-12 · Cited by 67
Fonseca, E., Silva, S., Rodrigues, C. F., Alves, C. T., Azeredo, J., & Henriques, M. (2014) · Biofouling · doi:10.1080/08927014.2014.886108 · Cited by 56 · cited 3×
“glabrata D1 (biofilms formed in a long continuous carpet (Hawser and Douglas 1995; Fonseca et al. 2014; Rodrigues and Henriques 2017), C.”
BackgroundSelf-citation
Cited by
Candida sp. Infections in Patients with Diabetes Mellitus
Rodrigues, C., Rodrigues, M., & Henriques, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010076 · Cited by 315
Self-citationHoušť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Transcriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
“auris, in Candida glabrata caspofungin treatment led to higher amounts of mannans on the cell wall [63].”
BackgroundSelf-citation
Metadata
- Authors
- Rodrigues, C. F., Rodrigues, M. E., & Henriques, M.
- Venue
- Biofouling
- Publisher
- Informa UK Limited
- Published
- 2018-05-25
- Volume
- 34
- Issue
- 5
- Pages
- 569-578
- ISSN
- 0892-7014 (ISSN-L)
- 1029-2454
- OpenAlex
- W2804745226
- Cited by
- 35
- References
- 31
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.